Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 226 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR NHL Player Carey Price Surprises 11-Year-Old Boy Who Just Lost Mom... June 24, 2019 John Cena Set The Record For Most Make-A-Wish Visits And He... March 4, 2019 Not Old Enough for Breast Cancer, She Demanded a Mammogram Anyway... September 16, 2020 How to Get More Support From Your Oncology Pharmacist During Cancer February 24, 2021 Load more HOT NEWS Reflections on Progress and Partnership at ASCO 2026 After Saving Thousands of Dogs, Tragedy Strikes Famed Rescue Family Resilience Isn’t About Bouncing Back Large Study Confirms that HPV Vaccine Prevents Cervical Cancer
